A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a multi-center, multi-cohort, open-label, phase Ib/II study to evaluate the efficacy,
safety, PK characteristics, immunogenicity and potential biomarkers of AK105 monotherapy in
the patients with selected advanced solid tumors.